FMARD Recruitment 2021  Yobe State SUBEB recruitment portal Federal Ministry of Foreign Affairs Recruitment

Health: Facts About New Cancer Drug That Cures Prostrate Cancer

1 min


 

Funder: NHMRC, Cancer Institute NSW, Cure Cancer Australia Foundation and Cancer Australia

 

Media release

From: Griffith University A new anti-cancer drug for prostate cancer overcomes the twin problems plaguing researchers for decades. It halts metastasis (tumour spread) and drug resistance.

Developed by Griffith University researcher Professor Des Richardson and colleagues from the University of Sydney, the drug known as DpC inhibits prostate specific antigen (PSA) as well as suppressing both androgen-dependent and independent arms of androgen receptor signalling.

“The current gold standard for prostate cancer treatment is androgen deprivation therapy to inhibit androgen receptors but eventually treatment leads to resistance in most men,’’ Professor Richardson said.

“This drug is the first to exhibit such potent androgen receptor suppression, critical for overcoming the development of androgen resistance, a major killer in prostate cancer.”

READ ALSO  BREAKING: European Countries Evacuate Citizens From Nigeria As COVID-19 Continues To Spread, Says Infections Could Rise To more Than 10,000 In The Coming Weeks

In an article published in the FASEB Journal, Professor Richardson and colleagues examined the effect of these new anti-cancer agents (including DpC) on prostate cancer.

“Our results demonstrate that our drug unexpectedly overcomes deadly oncogenic signalling by the hormone, testosterone,’’ he said.

“This finding was totally unexpected and very exciting, as for the first time we may be able to treat patients using a new therapy that is miles ahead of the current standard anti-cancer chemotherapy for prostate cancer, Enzalutamide”.

He said another important aspect of the paper was the finding that DpC could markedly reduce the expression of the well-known indicator of prostate specific antigen – PSA.

READ ALSO  Be Vigilant, Well Kitted At All Times While Attending To COVID-19 Patients — Ekpenyong Tells Health Workers

“PSA is a bad guy in prostate cancer patients, and the fact that DpC could markedly ablate this indicator was again very surprising and could be part of the way these drugs work to block the spread of prostate cancer.”

Professor Richardson is a new appointee (Alan Mackay Sim Distinguished Chair of Cancer Cell Biology and NHMRC Senior Principal Research Fellow) at the Griffith Institute for Drug Discovery based at Griffith University.

Over the past 25 years he has been developing unique anti-cancer drugs (dipyridyl thiosemicarbazones such as “DpC”) that have entered multi-centre Phase I clinical trials for the treatment for a range of highly resistant and difficult to treat tumours.

READ ALSO  Edo 2020: Fear Grips Oshiomhole As Obaseki Says Direct Primaries Can't Hold In His State

The current research was a collaboration with Dr Zaklina Kovacevic (University of Sydney) who was mentored by Professor Richardson through her PhD studies and also multiple post-doctoral fellowships over a period of 14 years leading to over 70 joint publications in quality international journals.

RSS
Jobs Vacancies in Nigeria


Like it? Share with your friends!

Jake Clifford

Jake Clifford is a Nigerian Born blogger and a fast growing Journalist, whose aim is to inform Nigerians with happening across Nigeria. Send story tips to him via [email protected] or

0 Comments

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.